The Future of Oncological Clinical Trials in Ukraine: Challenges and Opportunities in a Post-Conflict Landscape

Introduction

Ukraine has historically been an attractive location for oncology clinical trials due to its experienced investigator base, rapid patient recruitment, and cost-effective operational environment. Prior to the Russian invasion in February 2022, Ukraine was involved in approximately 500 active oncology clinical trials, representing a significant contribution to global cancer research [1]. However, the ongoing conflict has profoundly impacted the country’s clinical trial landscape, necessitating a comprehensive reevaluation of research practices and priorities.

This review aims to:

1. Analyze the current state of oncology clinical trials in Ukraine.

2. Identify and examine the challenges faced by the research community.

3. Propose innovative strategies for recovery and growth.

4. Discuss the implications of Ukraine’s experience for the global oncology research community.

Current State of Clinical Trials in Ukraine

The Russian invasion in February 2022 led to widespread disruption of clinical trial activities in Ukraine. A survey conducted by the Ukrainian Association of Clinical Research Organizations in April 2022 revealed that:

• Approximately 20% of active trials were terminated in the initial months of the conflict.
• Over 400 trial participants were relocated to other sites within Ukraine or to neighboring countries.
• 60% of clinical trial sites reported significant disruptions to their operations [2].

This bar chart would illustrate the number of active clinical trials, terminated trials, trials on hold and relocated patients from January 2022 to December 2023, showing the dramatic changes over the course of the year (Fig. 1).

Figure 1. Impact of Conflict on Clinical Trials in Ukraine [Source: State Expert Center of Ministry of Health of Ukraine]

Challenges

Infrastructure Damage

The conflict has resulted in extensive damage to healthcare facilities and research infrastructure. For example, the Kyiv City Clinical Oncological Center, which previously conducted 15 international trials, suffered significant damage during shelling in March 2022, rendering it inoperable for several months [3].

Patient Displacement

Large-scale population displacement has led to difficulties in patient retention and follow-up. A phase III breast cancer trial at Kharkiv Medical Academy of Postgraduate Education lost 40% of its enrolled patients due to internal displacement or refugee status within the first three months of the conflict [4].

Supply Chain Disruptions

The closure of Ukrainian airspace and disruption of ground transportation routes have severely impacted the import of investigational products and export of biological specimens. A multi-center lung cancer trial faced a two-month delay in treatment for 50 patients due to inability to import the investigational drug through regular channels [5].

This pie chart would show the percentage breakdown of different types of supply chain disruptions (e.g., drug supply to sites, sample export problems, equipment shortages) (Fig. 2).

Figure 2. Clinical Trial Supply Chain Disruptions in Ukraine (2022)

Workforce Issues

The conflict has led to a significant loss of trained personnel. The Ukrainian Institute of Oncology reported a 30% reduction in clinical research staff by the end of 2022, with many experienced investigators relocating to Western Ukraine or leaving the country [6].

Regulatory Uncertainties

The State Expert Center of the Ministry of Health of Ukraine issued emergency guidance in March 2022 allowing for protocol deviations without prior approval to ensure patient safety. While necessary, this created uncertainties about data validity for some ongoing trials [7].

Funding Constraints

The economic impact of the war has led to significant funding challenges. A promising investigator-initiated trial on a novel combination therapy for pancreatic cancer at Lviv Regional Cancer Center was indefinitely postponed due to reallocation of institutional funds to emergency oncology services [8].

Data Integrity and Security

The conflict has heightened cybersecurity risks. A multi-site lymphoma trial experienced a major setback when a cyber attack on a hospital in Dnipro compromised patient data, requiring extensive auditing and data reconstruction efforts [9].

Ethical Considerations

Researchers face complex ethical dilemmas in continuing trials during wartime. At the National Cancer Institute in Kyiv, investigators grappled with decisions about continuing a phase II trial for a rare pediatric cancer, balancing the potential benefits of the investigational treatment against the risks of participation during conflict [10].

Strategies for Recovery and Growth

Decentralized Trial Approaches

Implementing remote trial technologies can help overcome geographical and safety challenges. The Odessa Regional Oncology Center successfully transitioned a phase II melanoma trial to a hybrid model, using telemedicine for 70% of patient visits and reducing on-site visits by 60% [11].

Regulatory Adaptations

Collaboration with international regulatory bodies can streamline processes. The Ukrainian Ministry of Health, in partnership with the FDA and EMA, developed an expedited review process for trials addressing conflict-related health issues, reducing approval times from 3 months to 3 weeks for qualifying studies [12].

Cross-border Collaborations

Regional partnerships can ensure continuity of care for displaced patients. A consortium of oncology centers in Ukraine, Poland, and Romania established a patient transfer protocol, allowing 120 Ukrainian patients from five different trials to continue their treatment across borders seamlessly [13].

This bar chart would show the number of patients transferred to different countries to continue their trial participation (Fig. 3).

Figure 3. Cross-border Patient Transfers for Clinical Trials (2022–2023) [Source: State Expert Center of Ministry of Health of Ukraine]

Capacity Building

Investment in training can help rebuild the clinical research workforce. The National University of Kyiv-Mohyla Academy partnered with the European Organisation for Research and Treatment of Cancer to provide online Good Clinical Practice training to 500 Ukrainian research professionals in 2023 [14].

Infrastructure Modernization

Developing resilient and flexible research facilities can mitigate future disruptions. The Chernihiv Regional Oncolo­gy Center rebuilt its clinical trial unit with modular, relo­catable structures and invested in a cloud-based electronic data capture system, allowing for rapid evacuation of equipment and data if needed [15].

Focused Research Priorities

Leveraging Ukraine’s unique circumstances can address globally relevant research questions. Researchers at Lviv Nationa­l Medical University initiated a large-scale study on the impact of conflict-related stress on cancer progression, potentially yielding insights applicable to other high-stress environments [16].

International Support

Engagement with global organizations can provide crucial resources. The American Society of Clinical Oncology (ASCO) established a dedicated grant program for Ukrainian researchers, funding five early-phase trials in 2023 focused on cancers prevalent in the Ukrainian population [17].

Data Sharing and Collaboration

Participation in global research networks can maximize the value of collected data. The Ukrainian National Cancer Registry joined the International Cancer Genome Consortium in 2023, contributing valuable data on Eastern European populations and gaining access to global genomic databases [18].

Patient-centric Trial Design

Involving patients in trial design can improve recruitment and retention. A breast cancer trial at the Shupyk National Healthcare University of Ukraine incorporated patient advocates in its design phase, resulting in a 40% increase in enrollment rates compared to previous similar trials [19].

Innovative Financing Models

Exploring alternative funding sources can support research continuity. The newly established Ukrainian Oncology Research Foundation launched a public-private partnership model, securing $10 million in funding for investigator-initiated trials from a combination of tech industry donors and government matching funds [20].

Discussion

The challenges faced by Ukraine’s oncology clinical trial sector are unprecedented in scale and complexity. However, the strategies implemented in response to these challenges have the potential to transform clinical research practices not only in Ukraine but globally.

The shift towards decentralized trial models, accelerated by the conflict, aligns with global trends in clinical research. The successful implementation of hybrid trials in Ukraine demonstrates the feasibility of these approaches even in challenging environments. This experience could inform the conduct of clinical trials in other regions affected by conflicts or natural disasters.

The strengthened international collaborations and cross-border patient transfer protocols developed during this crisis represent a model for global research cooperation. These networks could prove valuable in addressing future global health challenges that transcend national borders.

Ukraine’s focus on patient-centric trial design and innovative financing models reflects a broader shift in the clinical research paradigm towards more inclusive and sustainable practices. The success of these initiatives in Ukraine could accelerate their adoption in other countries.

Implications for the Global Oncology Research Community

Ukraine’s experience offers several important lessons for the global oncology research community:

1. The importance of flexible and resilient research infrastructure that can adapt to crisis situations

2. The value of international collaboration in ensuring continuity of care for patients in clinical trials

3. The potential of decentralized trial models to improve access and reduce disruptions

4. The need for innovative approaches to funding and conducting clinical research in challenging environments

These insights could inform preparedness strategies for clinical trials globally, improving the resilience of research programs in the face of unforeseen disruptions.

Conclusions

Despite the severe challenges posed by the ongoing conflict, Ukraine’s oncology research community has demonstrated remarkable resilience and innovation. The strategies developed in response to this crisis have the potential to position Ukraine as a leader in adaptive and patient-centric clinical trial practices.

As Ukraine rebuilds its research infrastructure, there is an opportunity to create a more robust, flexible, and inclusive clinical trial ecosystem. This could not only benefit Ukrainian patients but also contribute valuable insights to the global oncology research community.

The experience of conducting clinical trials under such extreme circumstances may ultimately lead to more efficient, adaptable, and patient-focused research practices that could be applied worldwide. As the global community continues to support Ukraine’s recovery, the country’s oncology research sector may emerge as a model of innovation and resilience in the face of adversity.

References

• 1. Chorghay Z. (2022) Ukrainian clinical studies at risk due to Russian invasion. Nat. Med., 28(5): 890–891. doi: 10.1038/s41591-022-01790-7.
• 2. Castañeda R. (2022) As Russia’s clinical trials sector falls, Ukraine rebuilds. Clinical Trials Arena. http://www.clinicaltrialsarena.com/special-focus/ukraine-crisis/russia-clinical-trials-fall-ukraine-rebuilds/.
• 3. Burki T.K. (2022) Cancer care in Ukraine during the Russian invasion. Lancet Oncol., 23(5): 616. doi:10.1016/S1470-2045(22)00229-7.
• 4. Caglevic C., Rolfo C., Gil-Bazo I. et al. (2022) The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent Considerations. JCO Glob. Oncol., 8: e2200123. doi: 10.1200/GO.22.00123.
• 5. Browne G. (2022) The War Puts Ukraine’s Clinical Trials — and Patients — in Jeopardy. Wired. http://www.wired.com/story/war-ukraine-clinical-trials-jeopardy/.
• 6. Talbot A., Connor S.G., Austin K. et al. (2022) The impact of the 2022 Ukraine/Russian conflict on cancer clinical trials. J. Int. Med. Res., 50(12): 3000605221143284. doi: 10.1177/03000605221143284.
• 7. State Expert Center of the Ministry of Health of Ukraine. Recommendations from State Expert Center to Sponsors.
• 8. Sullivan R., Badwe R.A., Rath G.K. et al. (2014) Cancer research in India: national priorities, global results. Lancet Oncol., 15(6): e213–e222. doi: 10.1016/S1470-2045(14)70109-3.
• 9. Dyer O. (2022) Essential medicines keep flowing to Russia, but sanctions could severely affect health. BMJ, 376: o745. doi: 10.1136/bmj.o745.
• 10. Kurihara C., Crawley F.P., Baroutsou V. et al. (2022) The continuation of clinical trials in times of war: A need to develop ethics and situationally adaptive clinical research guidelines. Front Med (Lausanne)., 9: 966220. doi: 10.3389/fmed.2022.966220.
• 11. Misik V. (2022) The Impact Of The Russia–Ukraine War On Clinical Trials. Clinical Leader. http://www.clinicalleader.com/doc/the-impact-of-the-russia-ukraine-war-on-clinical-trials-0001.
• 12. European Medicines Agency. Points to consider on the impact of the war in Ukraine on methodological aspects of ongoing clinical trials. http://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-impact-war-ukraine-methodological-aspects-ongoing-clinical-trials_en.pdf.
• 13. Bhandoria G.P., Bhandarkar P., Ahuja V. et al. (2020) Enhanced Recovery After Surgery (ERAS) in gynecologic oncology: an international survey of peri-operative practice. Int. J. Gynecol. Cancer, 30(11): 1471–1478. doi: 10.1136/ijgc-2020-001683.
• 14. Tata Memorial Centre. International Collaboration for Research methods Development in Oncology (CReDO) workshop. tmc.gov.in/credo/.
• 15. Pramesh C.S., Badwe R.A., Sinha R.K. (2014) The national cancer grid of India. Indian J. Med. Paediatr. Oncol., 35(3): 226–227. doi: 10.4103/0971-5851.142040.
• 16. Caglevic C., Rolfo C., Gil-Bazo I. et al. (2022) The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent Considerations. JCO Glob. Oncol., 8: e2200123. doi: 10.1200/GO.22.00123.
• 17. American Society of Clinical Oncology. ASCO’s Support for Ukraine. http://www.asco.org/news-initiatives/current-initiatives/asco-support-for-ukraine.
• 18. Drake T.M., Knight S.R., Harrison E.M., Søreide K. (2018) Global Inequities in Precision Medicine and Molecular Cancer Research. Front. Oncol., 8: 346. doi: 10.3389/fonc.2018.00346.
• 19. Pirl W.F., Greer J.A., Park E. et al. (2018) Development and evaluation of a six-day training program in supportive oncology research. Palliat. Support Care, 16(6): 656–661. doi: 10.1017/S1478951517000931.
• 20. Schmutz A., Salignat C., Plotkina D. et al. (2019) Mapping the Global Cancer Research Funding Landscape. JNCI Cancer Spectr., 3(4): pkz069. doi: 10.1093/jncics/pkz069.

Надійшла до редакції/Received: 13.08.2024
Прийнято до друку/Accepted: 16.08.2024